膀胱癌精准化新辅助化疗研究进展  

Research progress of precision neoadjuvant chemotherapy for bladder cancer

作　　者：李云云 王自勇 韦海荣[1] 詹辉[1] 王海峰 王剑松[1] Yunyun Li;Ziyong Wang;Hairong Wei;Hui Zhan;Haifeng Wang;Jiansong Wang(Department of Urology,Second Affiliated Hospital of Kunming Medical University,Yunnan's Institute of Urology,Kunming 650101,China)

机构地区：[1]昆明医科大学第二附属医院泌尿外科,云南省泌尿外科研究所,昆明市650101

出　　处：《中国肿瘤临床》2019年第22期1177-1180,共4页Chinese Journal of Clinical Oncology

基　　金：国家自然科学基金研究项目(编号:81660423)资助。

摘　　要：根治性膀胱切除术(radical cystectomy,RC)是肌层浸润性膀胱癌(muscular invasive bladder cancer,MIBC)患者的标准治疗,术后5年总生存率仅约50%,而术前新辅助化疗(neoadjuvant chemotherapy,NAC)提高了患者的总生存率。虽各指南均推荐行NAC,但部分患者对NAC无治疗反应,不能从中获益。采用NAC治疗反应的筛选方法对行NAC的患者是否受益进行识别,是实现个体化、精准化治疗的关键所在,但在临床实践中目前尚无一种可靠的筛选方法。本文将对膀胱癌精准化NAC及NAC反应的筛选方法进行综述。Radical cystectomy is the standard treatment for patients with myometrial invasive bladder cancer.The overall 5-year survival rate is only approximately 50%;however,administering neoadjuvant chemotherapy before operation improves the overall survival rate.Although all guidelines recommend neoadjuvant chemotherapy,some patients do not respond to neoadjuvant chemotherapy and thus do not benefit from the therapy.It is essential to identify the benefits of neoadjuvant chemotherapy in patients by using neoadjuvant chemotherapy response screening methods;however,there is no reliable screening method in clinical practice.This article reviewsprecise neoadjuvant chemotherapy and neoadjuvant chemotherapy response screening methods for bladder cancer.

关 键 词：肌层浸润性膀胱癌 新辅助化疗 生物标志物 精准医疗 

分 类 号：R737.14[医药卫生—肿瘤]